Neurocrine Biosciences NBIX Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Based on the most recent quarter.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's current ratio?
- Neurocrine Biosciences (NBIX) reported current ratio of 2.9× in Q1 2026.
- How has Neurocrine Biosciences's current ratio changed year-over-year?
- Neurocrine Biosciences's current ratio decreased by 6.5% year-over-year, from 3.1× to 2.9×.
- What is the long-term trend for Neurocrine Biosciences's current ratio?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's current ratio has grown at a -9.3% compound annual growth rate (CAGR), from 19.3× to 13.1×.
- What does current ratio mean?
- Whether the company has enough short-term assets to cover its short-term bills.
- How do you interpret current ratio?
- Above 1.0 means short-term assets cover short-term liabilities. Very high values can signal idle cash or bloated inventory/receivables rather than strength — there's a healthy middle, not 'more is better'.
- How does current ratio compare across companies?
- Comparable within an industry. Working-capital-light businesses can operate safely below 1.0 by collecting before they pay.